PFE has been the subject of a number of other research reports. Piper Sandler upped their price objective on Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. Morgan Stanley upped their price objective on Pfizer from $36.00 to $42.00 and gave the company an equal weight rating in a research note on Thursday. SVB Leerink upped their price objective on Pfizer from $39.00 to $42.00 and gave the company a market perform rating in a research note on Wednesday. Barclays cut their target price on Pfizer from $37.00 to $35.00 in a research note on Monday, June 1st. Finally, Royal Bank of Canada reiterated a buy rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, July 20th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. Pfizer currently has an average rating of Hold and a consensus price target of $38.95.
Shares of PFE traded down $0.26 during trading hours on Thursday, hitting $38.48. The stock had a trading volume of 27,042,691 shares, compared to its average volume of 32,108,124. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. The firm has a 50 day simple moving average of $34.75 and a 200-day simple moving average of $35.79. The firm has a market capitalization of $213.75 billion, a P/E ratio of 15.27, a price-to-earnings-growth ratio of 3.10 and a beta of 0.68. Pfizer has a 1-year low of $27.88 and a 1-year high of $40.97.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be issued a $0.38 dividend. The ex-dividend date of this dividend is Thursday, July 30th. This represents a $1.52 annualized dividend and a yield of 3.95%. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the transaction, the senior vice president now directly owns 7,542 shares in the company, valued at approximately $272,492.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.08% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of PFE. Sunbelt Securities Inc. raised its position in Pfizer by 1.8% in the fourth quarter. Sunbelt Securities Inc. now owns 186,794 shares of the biopharmaceutical company’s stock valued at $7,319,000 after purchasing an additional 3,235 shares during the period. First National Bank of Mount Dora Trust Investment Services lifted its position in Pfizer by 5.1% during the 1st quarter. First National Bank of Mount Dora Trust Investment Services now owns 124,915 shares of the biopharmaceutical company’s stock valued at $4,077,000 after acquiring an additional 6,012 shares during the period. IMS Capital Management lifted its position in Pfizer by 249.3% during the 1st quarter. IMS Capital Management now owns 24,791 shares of the biopharmaceutical company’s stock valued at $809,000 after acquiring an additional 17,694 shares during the period. Woodstock Corp lifted its position in Pfizer by 0.6% during the 1st quarter. Woodstock Corp now owns 136,295 shares of the biopharmaceutical company’s stock valued at $4,449,000 after acquiring an additional 800 shares during the period. Finally, Fulton Bank N.A. lifted its position in Pfizer by 1.4% during the 1st quarter. Fulton Bank N.A. now owns 168,029 shares of the biopharmaceutical company’s stock valued at $5,484,000 after acquiring an additional 2,273 shares during the period. Institutional investors own 70.20% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Dividend Achievers
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.